Standigm applies cutting-edge AI technologies to drug discovery. AI and biology experts team up to build a real-world AI model for the pharmaceutical industry. We currently focus on predicting new indications for existing drugs, called drug repositioning through the deeply trained AI model with molecular features of drug responses and drug uses. Standigm generated tens of drug candidates for cancers, Parkinson’s disease (PD), autism, fatty liver diseases (NASH) and more. We promise practical benefits on time and cost in pharmaceutical industry by eliminating some of the uncertainty in the drug discovery process.
Total Funding: $15.2 M
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2015
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Standigm
Software Developers as AI Engineer
Seoul, Seoul-t'ukpyolsi
Researchers in Deep Learning/Machine Learning
Seoul, Seoul-t'ukpyolsi
